tiprankstipranks
Trending News
More News >

Tianjin Pharmaceutical Updates on Net Proceeds Utilization

Story Highlights
  • Tianjin Pharmaceutical Da Ren Tang Group operates in the pharmaceutical industry.
  • The company updated on net proceeds use from a share placement, ensuring regulatory compliance.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

The latest announcement is out from Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S ( (DE:2TZ) ).

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited has provided an update regarding the deposit and use of net proceeds from a previous share placement. The company issued 29,564,356 A-shares at RMB 28.28 per share, resulting in net proceeds of approximately RMB 814,340,000. This update aligns with regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange, ensuring transparency and compliance in the management of funds.

More about Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited, is a company incorporated in the People’s Republic of China. It operates in the pharmaceutical industry, focusing on the production and distribution of pharmaceutical products.

YTD Price Performance: 4.14%

Technical Sentiment Signal: Sell

Current Market Cap: €3.67B

Find detailed analytics on 2TZ stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App